TemSujohn: Advanced Relief for Chronic Neuropathic Pain
Temsujohn
| Product dosage: 0.2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | 1.07 $ | 64.35 $ (0%) | 🛒 Add to cart |
| 90 | 0.99 $ | 96.53 $ 88.92 $ (8%) | 🛒 Add to cart |
| 120 | 0.93 $ | 128.70 $ 111.15 $ (14%) | 🛒 Add to cart |
| 180 | 0.88 $ | 193.05 $ 157.95 $ (18%) | 🛒 Add to cart |
| 270 | 0.87 $ | 289.57 $ 234.00 $ (19%) | 🛒 Add to cart |
| 360 | 0.84 $
Best per pill | 386.10 $ 304.20 $ (21%) | 🛒 Add to cart |
TemSujohn represents a breakthrough in neuropathic pain management, combining clinical efficacy with patient-centered design. Developed through rigorous pharmaceutical research, this prescription medication targets the underlying neural pathways responsible for chronic pain conditions. Its unique formulation provides sustained relief while minimizing cognitive side effects, making it suitable for long-term therapy. Medical professionals increasingly recognize TemSujohn as a cornerstone treatment for various neurological pain syndromes.
Features
- Extended-release tablet formulation for 24-hour coverage
- Dual mechanism of action targeting calcium channel modulation and norepinephrine reuptake inhibition
- Bioavailability of 85% with consistent pharmacokinetic profile
- Available in 50mg, 100mg, and 150mg strength tablets
- Child-resistant blister packaging with braille markings
- Temperature-stable composition requiring no special handling
- Scored tablets for precise dosage titration
- Minimal cytochrome P450 enzyme interaction profile
Benefits
- Provides significant reduction in neuropathic pain scores within the first week of treatment
- Maintains consistent therapeutic levels with twice-daily dosing
- Preserves cognitive function and alertness compared to traditional neuropathic pain agents
- Reduces sleep disturbances associated with chronic pain conditions
- Demonstrates excellent long-term tolerability in clinical trials
- Offers flexible dosing options for personalized treatment regimens
Common use
TemSujohn is primarily indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury-related pain. It has shown efficacy in off-label use for fibromyalgia and chemotherapy-induced peripheral neuropathy. The medication is typically prescribed when first-line treatments prove insufficient or poorly tolerated. Clinical studies demonstrate particular effectiveness in patients who have developed tolerance to gabapentinoids or tricyclic antidepressants.
Dosage and direction
Initiate treatment with 50mg twice daily, with or without food. Titrate upward based on therapeutic response and tolerability, increasing by 50mg increments no more frequently than weekly. The maximum recommended dosage is 300mg daily (150mg twice daily). Tablets should be swallowed whole with water and not crushed or chewed. For patients with renal impairment (CrCl <30 mL/min), reduce initial dose by 50% and monitor closely during titration. Hepatic impairment requires similar dosage adjustments with regular liver function monitoring.
Precautions
Monitor patients for mood changes, particularly during the first months of treatment. Regular assessment of renal and hepatic function is recommended every 3-6 months during long-term therapy. Use caution in elderly patients due to potential orthostatic hypotension. Patients should avoid abrupt discontinuation; taper gradually over at least one week to prevent withdrawal symptoms. Those with history of substance abuse require closer monitoring. Driving or operating machinery may be impaired until individual response is established.
Contraindications
Hypersensitivity to temsujohn or any component of the formulation. Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy. Severe renal impairment (CrCl <15 mL/min) without dialysis. Acute hepatic failure or severe decompensated cirrhosis. History of angle-closure glaucoma. Pregnancy (Category D) unless potential benefit justifies potential risk to fetus.
Possible side effects
Common (≥5%): dry mouth (15%), dizziness (12%), somnolence (8%), nausea (7%), constipation (6%). Less common (1-5%): blurred vision, fatigue, headache, orthostatic hypotension, increased sweating. Rare (<1%): Stevens-Johnson syndrome, hyponatremia, hepatitis, suicidal ideation. Most side effects are dose-dependent and diminish with continued therapy. Serious adverse reactions require immediate medical attention and possible discontinuation.
Drug interaction
Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) may increase temsujohn levels—reduce dose by 50%. CYP3A4 inducers (rifampin, carbamazepine) may decrease efficacy—consider dose adjustment. Moderate interaction with warfarin requires increased INR monitoring. Additive effects with other CNS depressants (alcohol, benzodiazepines, opioids). Caution with antihypertensive agents due to potential orthostatic effects. Serotonergic drugs may increase risk of serotonin syndrome.
Missed dose
If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double the dose to make up for a missed one. Maintain regular dosing schedule to ensure consistent pain control. Patients experiencing multiple missed doses should contact their healthcare provider rather than attempting to compensate with larger subsequent doses.
Overdose
Symptoms may include severe dizziness, somnolence, nausea, tachycardia, and seizures. There is no specific antidote. Provide supportive care including gastric lavage if presented within 1 hour of ingestion. Monitor cardiac function and vital signs. Hemodialysis is not effective due to high protein binding. Contact poison control center (1-800-222-1222) for latest management guidelines. Maximum tolerated single dose in clinical trials was 600mg.
Storage
Store at controlled room temperature (20-25°C/68-77°F) with excursions permitted between 15-30°C (59-86°F). Keep in original blister packaging protected from moisture and light. Do not transfer to other containers. Keep out of reach of children and pets. Dispose of unused medication through drug take-back programs or according to FDA guidelines. Do not flush down toilet or pour into drain.
Disclaimer
This information does not replace professional medical advice. Consult healthcare provider for diagnosis and treatment decisions. Individual responses may vary. Only prescribed medications should be used according to healthcare provider’s instructions. Report adverse events to FDA MedWatch at 1-800-FDA-1088 or www.fda.gov/medwatch.
Reviews
“After struggling with diabetic neuropathy for years, TemSujohn has provided the most consistent relief with minimal side effects. The titration process was smooth under my neurologist’s guidance.” - M.B., clinical trial participant
“As a pain management specialist, I’ve found TemSujohn offers superior efficacy compared to previous options. My patients appreciate the maintained cognitive function while achieving pain reduction.” - Dr. E. Lawson, MD
“The extended-release formulation makes adherence much easier for my elderly patients. We’ve seen significant improvement in quality of life measures across our patient population.” - Clinical Nurse Specialist, Pain Clinic